DLL3 and lung carcinoma: Combined, these findings suggest that TTF1 protein expression (a routine clinical diagnostic IHC marker for lung cancer) could be a surrogate marker for DLL3 expression and, thus, help identify patients with DLL3-positive tumors (which have the highest response rates to rovalpituzumab tesirine).